Pura Vida Investments’s Sarepta Therapeutics SRPT Stock Holding History

Pura Vida Investments’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-200,000	Closed	-$25.9M	–	157
2022 Q4	$25.9M	Hold	200,000	–	–	1.34%	19
2022 Q3	$22.1M	Hold	200,000	–	–	1.28%	20
2022 Q2	$15M	Hold	200,000	–	–	0.87%	33
2022 Q1	$15.6M	Buy	+200,000	New	+$15.3M	0.51%	48
2021 Q1	–	Sell	-84,000	Closed	-$14.3M	–	254
2020 Q4	$14.3M	Buy	84,000 +30,000	+56%	+$4.45M	0.52%	51
2020 Q3	$7.58M	Buy	54,000 +3,000	+6%	+$456K	0.39%	52
2020 Q2	$8.18M	Buy	51,000 +1,000	+2%	+$136K	0.79%	33
2020 Q1	$4.89M	Buy	+50,000	New	+$5.72M	0.58%	44
2016 Q1	–	Sell	-5,400	Closed	-$208K	–	95
2015 Q4	$208K	Hold	5,400	–	–	0.09%	75
2015 Q3	$173K	Hold	5,400	–	–	0.1%	65
2015 Q2	$164K	Hold	5,400	–	–	0.08%	67
2015 Q1	$72K	Buy	+5,400	New	+$72K	0.04%	63

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pura Vida Investments's SRPT Position: Q2 2022 in Review

Pura Vida Investments sold out of Sarepta Therapeutics (SRPT) in Q2 2022, closing a stake of 25,850 shares — an estimated $1.9M sold.

Pura Vida Investments first reported a position in SRPT in Q3 2016 and held it in 5 quarters. The position peaked at $2.46M in Q3 2016. 332 funds tracked by Wall St. Rank hold SRPT as of Q2 2022.

Pura Vida Investments reported no remaining Sarepta Therapeutics position as of Q2 2022 after selling out during the quarter.
Pura Vida Investments sold 25,850 Sarepta Therapeutics shares in Q2 2022, an estimated $1.9M.
Pura Vida Investments first reported a position in Sarepta Therapeutics in Q3 2016 and held it in 5 quarters.
Pura Vida Investments's Sarepta Therapeutics position peaked at $2.46M in Q3 2016.
332 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2022.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.